PureTech Health plc (0VQ.F)

2,5000 0,0000 (0,00%) Börsenschluss: 08:05AM CEST

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 90

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Bharatt M. Chowrira J.D., Ph.D.	CEO & Executive Director	744,18k	N/A	1965
Ms. Daphne Zohar	Founder, Senior Advisor & Board Observer	935,21k	N/A	1971
Dr. Robert S. Langer Jr., Ph.D.	Co-Founder & Non-Executive Director	134,79k	N/A	1949
Dr. Eric Elenko Ph.D.	President	N/A	N/A	1973
Dr. David R. Elmaleh Ph.D.	Co-Founder & Senior Advisor	N/A	N/A	1948
Ms. Allison Mead Talbot	Head of Communications & Investor Relations	N/A	N/A	N/A
Mr. Charles Sherwood III, J.D., Ph.D.	General Counsel & Company Secretary	N/A	N/A	N/A
Mr. Spencer Ball	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Aleksandra Filipovic M.D., Ph.D.	Head of Oncology	N/A	N/A	N/A
Ms. Cheryl Murphy Ph.D.	Head of Grants Management & Strategy	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plcs ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 10, Vorstand: 2, Shareholderrechte: 1, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.